Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

A potent isoprenylcysteine carboxylmethyltransferase (ICMT) inhibitor improves survival in Ras-driven acute myeloid leukemia.

Marin-Ramos NI, Balabasquer M, Ortega-Nogales FJ, Torrecillas IR, Gil-Ordoñez A, Marcos-Ramiro B, Aguilar-Garrido P, Cushman I, Romero A, Medrano FJ, Gajate C, Mollinedo F, Philips MR, Campillo M, Gallardo M, Martín-Fontecha M, López-Rodríguez ML, Ortega-Gutierrez S.

J Med Chem. 2019 Jun 10. doi: 10.1021/acs.jmedchem.9b00145. [Epub ahead of print]

PMID:
31181882
2.

Safety and Tolerability of c-MET Inhibitors in Cancer.

Puccini A, Marín-Ramos NI, Bergamo F, Schirripa M, Lonardi S, Lenz HJ, Loupakis F, Battaglin F.

Drug Saf. 2019 Feb;42(2):211-233. doi: 10.1007/s40264-018-0780-x. Review.

PMID:
30649748
3.

The Rolipram-Perillyl Alcohol Conjugate (NEO214) Is A Mediator of Cell Death through the Death Receptor Pathway.

Cho HY, Thein TZ, Wang W, Swenson SD, Fayngor RA, Ou M, Marín-Ramos NI, Schönthal AH, Hofman FM, Chen TC.

Mol Cancer Ther. 2019 Mar;18(3):517-530. doi: 10.1158/1535-7163.MCT-18-0465. Epub 2019 Jan 15.

PMID:
30647121
4.

NEO212, a conjugate of temozolomide and perillyl alcohol, blocks the endothelial-to-mesenchymal transition in tumor-associated brain endothelial cells in glioblastoma.

Marín-Ramos NI, Jhaveri N, Thein TZ, Fayngor RA, Chen TC, Hofman FM.

Cancer Lett. 2019 Feb 1;442:170-180. doi: 10.1016/j.canlet.2018.10.034. Epub 2018 Oct 28.

PMID:
30392789
5.

NEO212: sub-cytotoxic doses capable of inhibiting glioma stem cell invasion.

Marín-Ramos NI, Hofman FM, Chen TC.

Oncoscience. 2018 Jun 27;5(5-6):148-149. doi: 10.18632/oncoscience.429. eCollection 2018 May. No abstract available.

6.

NEO212 Inhibits Migration and Invasion of Glioma Stem Cells.

Marín-Ramos NI, Thein TZ, Cho HY, Swenson SD, Wang W, Schönthal AH, Chen TC, Hofman FM.

Mol Cancer Ther. 2018 Mar;17(3):625-637. doi: 10.1158/1535-7163.MCT-17-0591. Epub 2018 Feb 13.

7.

Blocking Ras inhibition as an antitumor strategy.

Marín-Ramos NI, Ortega-Gutiérrez S, López-Rodríguez ML.

Semin Cancer Biol. 2019 Feb;54:91-100. doi: 10.1016/j.semcancer.2018.01.017. Epub 2018 Feb 2. Review.

PMID:
29409706
8.

Intratumoral delivery of bortezomib: impact on survival in an intracranial glioma tumor model.

Wang W, Cho HY, Rosenstein-Sisson R, Marín Ramos NI, Price R, Hurth K, Schönthal AH, Hofman FM, Chen TC.

J Neurosurg. 2018 Mar;128(3):695-700. doi: 10.3171/2016.11.JNS161212. Epub 2017 Apr 14.

PMID:
28409734
9.

Development of a Nucleotide Exchange Inhibitor That Impairs Ras Oncogenic Signaling.

Marín-Ramos NI, Piñar C, Vázquez-Villa H, Martín-Fontecha M, González Á, Canales Á, Algar S, Mayo PP, Jiménez-Barbero J, Gajate C, Mollinedo F, Pardo L, Ortega-Gutiérrez S, Viso A, López-Rodríguez ML.

Chemistry. 2017 Jan 31;23(7):1676-1685. doi: 10.1002/chem.201604905. Epub 2016 Dec 27.

PMID:
27885731
10.

Auranofin efficacy against MDR Streptococcus pneumoniae and Staphylococcus aureus infections.

Aguinagalde L, Díez-Martínez R, Yuste J, Royo I, Gil C, Lasa Í, Martín-Fontecha M, Marín-Ramos NI, Ardanuy C, Liñares J, García P, García E, Sánchez-Puelles JM.

J Antimicrob Chemother. 2015 Sep;70(9):2608-17. doi: 10.1093/jac/dkv163. Epub 2015 Jul 4.

PMID:
26142477
11.

New inhibitors of angiogenesis with antitumor activity in vivo.

Marín-Ramos NI, Alonso D, Ortega-Gutiérrez S, Ortega-Nogales FJ, Balabasquer M, Vázquez-Villa H, Andradas C, Blasco-Benito S, Pérez-Gómez E, Canales Á, Jiménez-Barbero J, Marquina A, del Prado JM, Sánchez C, Martín-Fontecha M, López-Rodríguez ML.

J Med Chem. 2015 May 14;58(9):3757-66. doi: 10.1021/jm5019252. Epub 2015 May 4.

PMID:
25906180

Supplemental Content

Loading ...
Support Center